| pubmed-article:15623547 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C0023980 | lld:lifeskim |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C0003316 | lld:lifeskim |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:15623547 | lifeskim:mentions | umls-concept:C0037791 | lld:lifeskim |
| pubmed-article:15623547 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15623547 | pubmed:dateCreated | 2005-1-19 | lld:pubmed |
| pubmed-article:15623547 | pubmed:abstractText | Persistent human papillomavirus (HPV) type 16 and 18 infection can lead to pre-malignant and malignant diseases of the lower genital tract. Several lines of evidence suggest that T cell responses can control HPV infection. However, relative to other human viruses, strong effector memory T cell responses against HPV have been difficult to detect. We used an in vitro stimulation step prior to enzyme-linked immunospot assays to identify IFN-gamma-secreting T cells specific for HPV16 and 18 E6/E7 peptides. This allowed the detection of HPV-specific CD4+ T cells that were not evident in direct ex vivo assays. T cell responses against HPV16 or 18 peptides were detected in healthy volunteers (7/9) and patients with lower genital tract neoplasia (10/20). Importantly, this assay allowed tracking of vaccine-induced T cell responses in nine patients, following inoculation with a live recombinant vaccinia virus (HPV16 and 18 E6/E7, TA-HPV). Novel vaccine-induced T cell responses were demonstrated in five patients, but no clinical responses (lesion regressions) were seen. For one vaccinated patient, the T cell response was mapped to a single dominant HPV18 E7 epitope and this response was sustained for >3 years. Our data suggest that systemic memory T cells against HPV16 and 18, induced naturally or by TA-HPV vaccination, are relatively rare. Nevertheless, the assay system developed allowed estimation of magnitude, epitope specificity, and longevity of vaccine-induced CD4+ T cell responses. This will be useful for vaccine design and measurement of immunological endpoints in clinical trials. | lld:pubmed |
| pubmed-article:15623547 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15623547 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15623547 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15623547 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:15623547 | pubmed:issn | 0953-8178 | lld:pubmed |
| pubmed-article:15623547 | pubmed:author | pubmed-author:ManStephenS | lld:pubmed |
| pubmed-article:15623547 | pubmed:author | pubmed-author:GallagherKath... | lld:pubmed |
| pubmed-article:15623547 | pubmed:author | pubmed-author:TristramAmand... | lld:pubmed |
| pubmed-article:15623547 | pubmed:author | pubmed-author:FianderAlison... | lld:pubmed |
| pubmed-article:15623547 | pubmed:author | pubmed-author:SmithKelly... | lld:pubmed |
| pubmed-article:15623547 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15623547 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:15623547 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15623547 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15623547 | pubmed:pagination | 167-76 | lld:pubmed |
| pubmed-article:15623547 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:meshHeading | pubmed-meshheading:15623547... | lld:pubmed |
| pubmed-article:15623547 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15623547 | pubmed:articleTitle | Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18. | lld:pubmed |
| pubmed-article:15623547 | pubmed:affiliation | Section of Infection and Immunity, Wales College of Medicine, Cardiff University, Henry Wellcome Research Building, Heath Park, Cardiff CF14 4XX, UK. | lld:pubmed |
| pubmed-article:15623547 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15623547 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:15623547 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15623547 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15623547 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15623547 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15623547 | lld:pubmed |
